SPORE in Lung Cancer

描述（由申请人提供）：在过去的40年里，肺癌的5年生存率与所有癌症的5年生存率保持同步。然而，这一比例仍低至-15%，令人失望。5年生存率的提高是由于认识的提高、检测技术的改进、对各种治疗方案患者的更好选择以及选择性使用姑息性干预措施的结果。然而，肺癌死亡率仍然非常高，它是后代判断我们是否成功有效防治这一疾病的基准。Moffitt Cancer Center SPORE in Lung Cancer将1)阐明肺癌发生和肿瘤进展中关键分子的作用机制，并研究它们对治疗效果的影响；2)前瞻性评估这些分子在治疗和预防干预方面的临床应用。我们的最终目标是改变肺癌高危人群和肺癌患者的护理标准。SPORE有五个转化研究项目，三个核心项目，一个发展研究项目和一个职业发展项目。

DESCRIPTION (provided by applicant): The 5-year survival from lung cancer has kept pace with the improvement in 5-year survival from all cancers over the last 40 years. Yet, it remains disappointingly low at -15%. This improvement in 5-year survival is a result of heightened awareness, better technology for detection, better selection of patients for various therapeutic options, and the selective use of palliative interventions. However, lung cancer mortality remains extraordinarily high, and it is the benchmark by which future generations will judge our success in effectively combating this disease. The Moffitt Cancer Center SPORE in Lung Cancer will 1) elucidate mechanisms of action of crucial molecules in lung carcinogenesis and tumor progression and investigate their impact on therapeutic efficacy and 2) prospectively assess the clinical utility of the molecules for therapeutic and prevention interventions. Our ultimate goal is to change the standard of care for people at risk for and with lung cancer. The SPORE has five translational research projects, three cores, a developmental research program, and a career development program. The projects are: 1) E2Fs Impact on Therapeutic Efficacy (Cress, Chen & Bepler) 2) RRM1 in the Management of Lung Cancer (Bepler, Cress & Simon) 3) Antitumor Mechanisms of Src Inhibitors in Lung Cancer (Haura, Cheng & Pledger) 4) Lung Cancer Chemoprevention with Enzastaurin (Bepler & Alexandrow) 5) p53-Based Vaccine for Small Cell Lung Cancer (Gabrilovich & Antonia) They are support by: A) Tissue Procurement, Pathology, and Bioinformatics Core (Altiok & Fenstermacher) B) Clinical Trials & Biostatistics Core (Simon, Schell & Bepler) C) Administration & Patient Advocacy Core (Bepler, Cress & Quinn). The SPORE also has Developmental Research & Career Development Programs. This SPORE will be firmly integrated into the H. Lee Moffitt Cancer Center and Research Institute, a free-standing, NCI designated Comprehensive Cancer in Tampa, Florida.